Goldman Sachs maintained its Sell rating despite raising its target price to Rs 1,750 from Rs 1,700, citing expensive valuations. Kotak downgraded the stock to Add with a target price of Rs 2,300.
Goldman Sachs maintained its Sell rating despite raising its target price to Rs 1,750 from Rs 1,700, citing expensive valuations. Kotak downgraded the stock to Add with a target price of Rs 2,300.
<iframe src="https://hindustansphere.com/embed/cluster/6c19a13ffddce8009062da6d74791d28f51c3f16" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Dr Lal PathLabs Q2 Review: Growth Guidance Raised, But Goldman Sachs Still Sees Valuation Risks"></iframe>
